MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), formerly, Lion Biotechnologies (NASDAQ:LBIO)*
Organization & Developments: Iovance
Parents
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), formerly, Lion Biotechnologies (NASDAQ:LBIO)*
Children
*Focused on developing unique cancer immunotherapies based on tumor infiltrating lymphocytes {TILs}
*Management has entered into several strategic partnerships with leading academic and government institutions, including the National Cancer Institute, MD Anderson, Moffitt Cancer Center, and Karolinska Institute in Europe
*Their approach to cancer therapeutics is referred to as adoptive T-cell therapy.
2019: IBI Report On Iovance: Are There Further Upsides To This Grower?_seekingalpha.com
2019: Iovance Biotherapeutics: Updating The Investment Thesis - Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
2019: Iovance: Assessing The Potential For Further Upside_seekingalpha.com
2019: Revisiting Iovance Biotherapeutics - Bret Jensen
2020: Despite Setback, Iovance's Lifileucel Remains A Multibillion Dollar Prospect
2020: Iovance revels in promising lung cancer data out of Moffitt as TIL therapy triggers 2 complete responses – Endpoints News
2020: Why This Biotech Stock Is Planning To Gene Edit Its Cancer Drugs_www.investors.com
2021: Iovance Biotherapeutics: The Frontier Of Novel Cancer Treatment
2022: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)_ seekingalpha.com
2023: Iovance Biotherapeutics: Good Trade Setup Created By The FDA Delay Gets Even Better
2023: Iovance Biotherapeutics: Testing Shareholders' Patience
2023: Iovance Biotherapeutics: The Easiest Money May Have Been Made, But Approval Does Seem Likely_seekingalpha.com
2024: 3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
2024: A Close Look At Iovance Biotherapeutics' Accelerated Approval
2024: Behind the new kind of cell therapy that just won FDA approval
2024: Industry Analysts Just Made A Sizeable Upgrade To Their Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Revenue Forecasts
2024: Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity_ seekingalpha.com
2024: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is largely controlled by institutional shareholders who own 62% of the company
2024: Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't
2024: Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
2024: Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date_ seekingalpha.com
2024: Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
2024: Iovance Biotherapeutics: Steady Progress_ seekingalpha.com
2024: Iovance Biotherapeutics' SWOT analysis: promising launch boosts cancer therapy stock
2024: Iovance: Approval For Historic Solid Tumor Targeting TIL Therapy Likely, Outlook Promising_ seekingalpha.com
2024: Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)
2024: US FDA grants accelerated approval for Iovance's skin cancer cell therapy
2025: Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25
2025: Iovance: Amtagvi's Rocky Launch And Mounting Concerns Lead To A 'Sell' Rating
2025: Iovance: The Company Makes It Hard To Estimate Revenue Growth
2025: Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)
2025: No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed
2025: Why Iovance Biotherapeutics (IOVA) Is Among the Best Low Priced Biotech Stocks t
2025:: Iovance Biotherapeutics: Abysmal Q1 2025 Performance Creates Buying Opportunity
Jumps
*Key People: Iovance
Finance & Acquisitions: Iovance